High levels of Drp1 affect T cell activation by enhancing the T cell-induced suppression of lung cancer cells, which increases CD8+ T cell infiltration into the tumor and amplifies the immune system response to treatment with the PD-1 inhibitor pembrolizumab [85]. The gene discussed is PDCD1; the disease is neoplasm.